Evidence map›Paper›PMID 29850694›Full record

ArticleBiomaterials science2018

Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections.

Fang-Yi Su, Jasmin Chen, Hye-Nam Son, Abby M Kelly, Anthony J Convertine, T Eoin West, Shawn J Skerrett, Daniel M Ratner, Patrick S Stayton

Open access · greenAbstract read
In one paragraph

Article in Biomaterials science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Mannose Ligands for Mannose Receptor Targeting.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Review
  7. Nanomaterials for Delivering Antibiotics in the Therapy of Pneumonia.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Mannose Conjugated Polymer TargetingACS infectious diseases · 2020
    Article
  16. Potential therapeutic approaches for a sleeping pathogen: tuberculosis a case for bioinorganic chemistry.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020
    Review
  17. Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fang-Yi SuDepartment of Bioengineering, University of Washington, Seattle, WA 98195, USA. dratner@uw.edu stayton@uw.edu.
Jasmin Chen
Hye-Nam Son
Abby M Kelly
Anthony J Convertine
T Eoin West
Shawn J Skerrett
Daniel M Ratner
Patrick S Stayton
University of Washington · US

Funding

Engineered Antimicrobial Platform to Target Pulmonary Intracellular InfectionsR01AI134729 · NIAID · UNIVERSITY OF WASHINGTON · PI Shawn J. Skerrett, Patrick S. Stayton · 2018 to 2026
$4.9M
NIAID NIH HHS R01 AI134729
6 · The paper itself

Abstract

Pulmonary intracellular infections, such as tuberculosis, anthrax, and tularemia, have remained a significant challenge to conventional antibiotic therapy. Ineffective antibiotic treatment of these infections can lead not only to undesired side effects, but also to the emergence of antibiotic resistance. Aminoglycosides (e.g., streptomycin) have long been part of the therapeutic regiment for many pulmonary intracellular infections. Their bioavailability for intracellular bacterial pools, however, is limited by poor membrane permeability and rapid elimination. To address this challenge, polymer-augmented liposomes (PALs) were developed to provide improved cytosolic delivery of streptomycin to alveolar macrophages, an important host cell for intracellular pathogens. A multifunctional diblock copolymer was engineered to functionalize PALs with carbohydrate-mediated targeting, pH-responsive drug release, and endosomal release activity with a single functional polymer that replaces the pegylated lipid component to simplify the liposome formulation. The pH-sensing functionality enabled PALs to provide enhanced release of streptomycin under endosomal pH conditions (70% release in 6 hours) with limited release at physiological pH 7.4 (16%). The membrane-destabilizing activity connected to endosomal release was characterized in a hemolysis assay and PALs displayed a sharp pH profile across the endosomal pH development target range. The direct connection of this membrane-destabilizing pH profile to model drug release was demonstrated in an established pyranine/p-xylene bispyridinium dibromide (DPX) fluorescence dequenching assay. PALs displayed similar sharp pH-responsive release, whereas PEGylated control liposomes did not, and similar profiles were then shown for streptomycin release. The mannose-targeting capability of the PALs was also demonstrated with 2.5 times higher internalization compared to non-targeted PEGylated liposomes. Finally, the streptomycin-loaded PALs were shown to have a significantly improved intracellular antibacterial activity in a Francisella-macrophage co-culture model, compared with free streptomycin or streptomycin delivered by control PEGylated liposomes (13× and 16×, respectively). This study suggests the potential of PALs as a useful platform to deliver antibiotics for the treatment of intracellular macrophage infections.

Indexed as

AnimalsAnti-Bacterial AgentsArylsulfonatesDrug CompoundingDrug Delivery SystemsDrug LiberationEndosomesFluorescent DyesFrancisella tularensisHydrogen-Ion ConcentrationKineticsLiposomesMannoseMethacrylatesMicePhosphatidylcholines1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)Anti-Bacterial AgentsArylsulfonatesFluorescent DyesLiposomesMannoseMethacrylatesPhosphatidylcholinesPhosphatidylethanolaminesPolyethylene GlycolspyraninePyridinium CompoundsStreptomycin

Identifiers

PMID29850694
PMCPMC6195317
OpenAlexW2806900749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.